Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Net debt / EBITDA

Net debt / EBITDA at other companies

Gilead Sciences logo
Gilead SciencesGILD
1.4×-0.6×
ALN
Alnylam PharmaceuticalsALNY
-1.4×—
Arrowhead Research logo
Arrowhead ResearchARWR
-0.3×—
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-1.6×—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-0.2×-1.4×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
0.3×+0.2×

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%—

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

net debt/ebitda=-116.1×

Based on the most recent quarter.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045

FAQ

What is Mirum Pharmaceuticals, Inc.'s net debt / EBITDA?
Mirum Pharmaceuticals, Inc. (MIRM) reported net debt / EBITDA of -116.1× in Q4 2025.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Ask your AI about Mirum Pharmaceuticals, Inc.'s net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude